AstraZeneca shares fall 7% after cancer drug Gefitinib plea shot down
- Bihar: School director dies after mob assault over death of two students
- PM spoke about Rakhi, but neglected Muslims during 'Ramzan': Congress
- Watch video: CCTV captures Mumbai local ramming into station
- Another Vyapam scam accused dies; 24th death in the case
- Sushma's Ministry declines info under RTI on Lalit Modi's passport issue
Shares of AstraZeneca Pharma today tumbled over 7 per cent, after the Intellectual Property Appellate Board (IPAB) turned down the drug firm's plea for a patent on the lung cancer drug Gefitinib.
Following the move, shares of the company opened weak and as the trade progressed it tanked 7.38 per cent to Rs 1,449.50 on the BSE.
At NSE, the scrip slipped 7.65 per cent to Rs 1,444.05.
Reacting on the development, the company said it is disappointed and is evaluating its options.
"We are disappointed by the Intellectual Property Appellate Board's decision.
We are confident in the validity of the claims in this patent application and are now evaluating our next steps," AstraZeneca said in a statement.
IPAB on November 26 upheld its earlier decision to refuse AstraZeneca a patent claim in 2007, citing lack of invention.
Decline in the stock was in contrast with a robust stock market where the benchmark index Sensex was trading at 19,093.42, up 251.34 points.